D
DSS, INC.
DSSCIK 0000771999NYSENon-AcceleratedSmaller ReportingPaperboard Containers & BoxesNew YorkFY ends Dec 31
Period
FY 2025
Revenue
$20.76M
Net Income
$-23.93M
Total Assets
$67.63M
Equity
$-832.0K
Shares Out
10.04M
Op. Cash Flow
$-9.13M
Business
DSS, Inc. is a diversified holding company operating four reportable business segments: Product Packaging (custom folding cartons, security printing, and mailers via wholly-owned Premier Packaging); Biotechnology (drug discovery and development of therapeutics, sugar substitutes, and botanical compounds via DSS BioHealth Security); Commercial Lending (commercial credit facilities and loan servicing through American Pacific Financial); and Securities and Investment Management (broker-dealer activities, REIT management, and investment advisory through Sentinel Brokers and affiliated entities). The company serves markets in North America and Asia across pharmaceutical, nutraceutical, consumer goods, healthcare, and financial services sectors.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 21 | 19 | 26 | 47 | 20 | |
| Cost of revenue | 23 | 24 | 25 | 40 | — | |
| Selling, general and administrative (including stock-based compensation) | 12 | 38 | 51 | 54 | 27 | |
| Total costs and expenses | 35 | 62 | 77 | 94 | 44 | |
| Operating loss | −14 | −43 | −51 | −46 | −24 | |
| Interest income | 19,000 | 238,000 | 1 | 629,000 | 5 | |
| Interest income on note receivable, related party | 32,000 | 102,000 | 171,000 | — | — | |
| Dividend income | 20,000 | — | 16,000 | 159,000 | — | |
| Other | 11,000 | 218,000 | 532,000 | 4 | 825,000 | |
| Interest expense | −266,000 | −283,000 | −553,000 | −126,000 | −196,000 | |
| Foreign Currency Translation Adjustment | — | −6,000 | — | — | — | |
| Gain on extinguishment of debt | 595,000 | — | — | 110,000 | 116,000 | |
| (Loss)/gain on equity method investment | −16,000 | 1,000 | −34,000 | 129,000 | −10 | |
| (Loss) gain on investments | −807,000 | 224,000 | −5 | −11 | −12 | |
| Impairment of investment | — | −782,000 | — | — | — | |
| Impairment of intangible assets | −600,000 | — | −7 | — | — | |
| Impairment of real estate assets | −2 | −7 | — | — | — | |
| Provision for loan losses | — | −4 | −4 | — | — | |
| (Loss)/gain on sale real estate assets | −10 | 165,000 | −1 | — | — | |
| Loss from operations before income taxes | −27 | −54 | −74 | −69 | −40 | |
| Income tax benefit | — | −8,000 | −4,000 | −172,000 | 4 | |
| Net loss | −27 | −54 | −78 | −70 | −34 | |
| Loss from operations attributed to noncontrolling interest | 4 | 7 | 17 | 10 | 921,000 | |
| Net loss attributable to DSS common stockholders | −24 | −47 | −61 | −60 | −33 | |
| Basic | −2.66 | −6.63 | −0.47 | — | — | |
| Diluted | −2.66 | −6.63 | −0.47 | — | — | |
| Basic (shares) | 9 | 7 | 7 | 6 | 52 | |
| Diluted (shares) | 9 | 8 | 7 | 6 | 52 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-06-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 6 | 11 | 7 | — | 19 | |
| Restricted cash | 100,000 | — | — | — | — | |
| Accounts receivable, net | 2 | 3 | 4 | — | 8 | |
| Inventory | 2 | 2 | 3 | — | 8 | |
| Investment in trading securities | 3 | 3 | — | — | — | |
| Assets held for sale | — | 45 | — | — | — | |
| Prepaid expenses and other current assets | 649,000 | 1 | 839,000 | — | 2 | |
| Total current assets | 14 | 67 | 75 | — | 48 | |
| Property, plant and equipment, net | 5 | 5 | 6 | — | 13 | |
| Investments in real estate, net | 17 | — | — | — | — | |
| Investments, cost method | 500,000 | 500,000 | — | — | — | |
| Investments, equity method | 113,000 | 129,000 | 128,000 | — | 162,000 | |
| Investment in equity securities | 7 | 6 | 10 | — | 27 | |
| Other assets | 71,000 | 162,000 | 97,000 | — | 3 | |
| Right-of-use assets | 6 | 6 | 7 | — | 8 | |
| Goodwill | 2 | 2 | 27 | — | 61 | |
| Other intangible assets, net | 17 | 19 | 20 | — | 31 | |
| Total assets | 68 | 106 | 153 | — | 249 | |
| Accounts payable | 3 | 3 | 4 | — | 6 | |
| Accrued expenses and deferred revenue | 2 | 3 | 3 | — | 19 | |
| Other current liabilities | 4 | 4 | 983,000 | — | 447,000 | |
| Accrued interest on long-term debt | 7 | 5 | — | — | — | |
| Current portion of lease liability | 611,000 | 606,000 | 686,000 | — | 796,000 | |
| Current portion of long-term debt on assets held-for-sale, net | — | 49 | 44 | — | — | |
| Total current liabilities | 47 | 65 | 56 | — | 74 | |
| Long-term debt, net | 6 | 2 | 7 | — | 10 | |
| Long term lease liability | 6 | 6 | 7 | — | 8 | |
| Total liabilities | 59 | 74 | — | — | — | |
| Commitments and contingencies (Note 16) | — | — | — | — | — | |
| Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding | — | — | — | — | — | |
| Common stock, $.02 par value; 200,000,000 shares authorized, 9,092,518 shares issued and outstanding (8,092,518 on December 31, 2024) | 182,000 | 161,000 | 140,000 | — | 139,000 | |
| Additional paid-in capital | 326 | 323 | 320 | — | 320 | |
| Accumulated deficit | −327 | −303 | −256 | 19 | −194 | |
| Total stockholders equity of the Company | −832,000 | 20 | 64 | — | 126 | |
| Non-controlling interest in subsidiaries | 10 | 13 | 19 | — | 31 | |
| Total stockholders equity | 9 | 33 | 83 | — | 157 | |
| Total liabilities and stockholders equity | 68 | 106 | 153 | — | 249 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 3 | 2 | 5 | — | — | |
| Issuance of common stock for reward | 870,000 | — | — | — | — | |
| Stock based payments for professional services rendered | 190,000 | — | — | — | — | |
| Stock based payments to employees and directors | 13,000 | 19,000 | — | 4,000 | 78,000 | |
| (Loss) gain on equity method investment | 16,000 | −1,000 | 34,000 | — | — | |
| Unrealized loss (gain) on investment in marketable securities | 531,000 | −224,000 | — | — | — | |
| Amortization of operating lease ROU assets | 640,000 | 745,000 | — | — | — | |
| Write off of inventory | 419,000 | — | — | — | — | |
| Provision for inventory obsolescence | −127,000 | — | — | — | — | |
| Loss (gain) on sale of real estate assets | 10 | −14,000 | 1 | — | — | |
| Impairment of fixed assets | — | 264,000 | — | — | — | |
| Impairment of investments of investments at cost | — | 782,000 | — | — | — | |
| Impairment of real estate | 2 | 7 | — | — | — | |
| Provision for loan losses | 20,000 | 4 | — | — | — | |
| Impairment of goodwill | — | 25 | 31 | — | — | |
| Accounts receivable | 558,000 | 1 | 1 | −2 | −2 | |
| Inventory | 152,000 | 377,000 | 5 | 540,000 | −6 | |
| Prepaid expenses and other current assets | 642,000 | 778,000 | 996,000 | 2 | −2 | |
| Investment in trading securities | −316,000 | −3 | — | — | — | |
| Other assets | 91,000 | −65,000 | 2 | −2 | 1 | |
| Accounts payable | −196,000 | −861,000 | −2 | 4 | 463,000 | |
| Accrued expenses | −926,000 | 140,000 | −16 | 4 | 16 | |
| ROU liabilities | −614,000 | −686,000 | −1 | — | — | |
| Accrued interest on notes payable | 2 | 4 | — | — | — | |
| Other liabilities | −624,000 | 3 | −39,000 | −298,000 | −2 | |
| Net cash used by operating activities | −9 | −9 | −19 | −27 | −9 | |
| Purchase of property, plant and equipment | −268,000 | −133,000 | — | — | — | |
| Purchase of real estate | −38,000 | −140,000 | — | — | — | |
| Proceeds from sale of real estate | 16 | — | — | — | — | |
| Proceeds from sale of equity investments | — | 3 | — | — | — | |
| Proceeds from disposal of property, plant and equipment | — | 6 | 248,000 | — | — | |
| Proceeds from sale of investment, related party | 2 | — | — | — | — | |
| Issuance of new notes receivable, net origination fees | — | −459,000 | — | — | — | |
| Payments received on notes receivable | 250,000 | 4 | 870,000 | 1 | — | |
| Payments received on notes receivable, related party | — | 106,000 | — | — | — | |
| Net cash provided by investing activities | 18 | 12 | 9 | −18 | −122 | |
| Payments of long-term debt | −18 | −3 | −4 | −4 | −2 | |
| Borrowings of long-term debt, net | 3 | 876,000 | — | — | — | |
| Borrowings of convertible note payable - related party | 500,000 | — | — | — | — | |
| Issuances of common stock, net of issuance costs | — | 3 | — | 2 | 122 | |
| Net cash provided (used) by financing activities | −14 | 1 | −2 | 8 | 179 | |
| Net increase (decrease) in cash | −5 | 5 | −9 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is DSS, INC.'s CIK number?
DSS, INC.'s SEC CIK number is 0000771999 (771999). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find DSS, INC.'s SEC filings?
All of DSS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.